4D-150 in Patients With Diabetic Macular Edema

NCTID	NCT05930561 (View at clinicaltrials.gov)
Description	Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME). (Show More)
Indication	Diabetic Macular Edema
Compound Name	4D-150
Sponsor	4D Molecular Therapeutics
Funder Type	Industry
Status	Recruiting
Enrollment Count	72

Target Gene/Variant	MiVEGFC
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV
Editor Type
Dose 1	Dose range: 5 x 10^9 -3 x 10^10 vg/eye
Dose 2	Planned Phase III dose: 3x10^10 vg/eye
Dose 3
Dose 4
Dose 5

No.of Trial Sites	15
Locations	Puerto Rico,United States

Has US IND	True
Recent Updates	Interim Phase 2 analysis: Q4 2024